The Value of Annual PET/CT as a Screening Tool for Myeloma Patients

In last week's blog, “How to Be Safer as You Live Longer,” IMF Chairman Brian Durie, MD cited the value of annual PET/CT as a screening tool to monitor low-level myeloma, detect hidden infection or an early second cancer. But what should a patient know when Medicare and supplemental insurance companies don't cover the cost? In this week's blog, Dr. Durie offers support for patients attempting to obtain reimbursement for these screenings. Click HERE to read.
Source: International Myeloma Foundation - Category: Hematology Source Type: news